Cathepsin K in treatment monitoring following intravenous zoledronic acid

Jahn, O.; Wex, Thomas; Klose, Silke; Kropf, Siegfried; Adolf, Daniela; Piatek, Stefan

doi:10.3892/br.2014.360

Cited by 3 publications

(2 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cathepsin-K (CathK) is mainly expressed in osteoclasts and is essential for bone resorption. [ 12 ] High levels of CathK are seen in osteoporotic women. [ 13 14 ] We studied the correlation between BMD, HCY, and CathK in postmenopausal women.…”

Section: Introductionmentioning

confidence: 99%

Relation of bone mineral density with homocysteine and cathepsin K levels in postmenopausal women

Mittal

Verma

Mishra

et al. 2018

Indian J Endocr Metab

View full text Add to dashboard Cite

Background:Homocysteine (HCY) interferes with collagen cross-linking in bones and stimulates osteoclast activity. The activated osteoclasts secrete cathepsin K (CathK), a cysteine protease, in eminent quantity during bone resorption. Hyperhomocysteinemia may effect bone mineral density (BMD) through CathK. We, therefore, examined the relation between HCY and BMD along with CathK, 25-hydroxyvit-D (25[OH]D), intact parathyroid hormone (iPTH), and Vitamin B12.Materials and Methods:We recruited a total of 93 postmenopausal women between the age group of 45–60 years, attending the Endocrinology outpatient department at King George's Medical University, Lucknow. BMD was done by DXA scan using Hologic QDR1000 system. Based on the WHO criteria, patients were segregated into three groups as follows; normal bone mass, osteopenia, and osteoporosis. All women underwent routine biochemical laboratory parameters, HCY, Vitamin B12, and CathK levels.Results:Among 93 postmenopausal women, 56% (52) had osteoporosis. Nineteen percent (18) had normal BMD (mean age, 53.22 ± 8.5 years) and 23 (25%) had osteopenia (mean age 52.86 ± 6.67 years). The mean age in the osteoporetic group was 56.2 ± 6.9 years. The median (interquartile range) levels of HCY in the three groups were 14.5 μmol/L (12.2–24.7), 15.05 μmol/L (12.1–19.9) and 13.2 μmol/L (10.3–17.0), respectively. CathK levels were similar in three groups 7.6 ng/ml (7.0–80.5), 8.3 ng/ml (7.3–8.5), and 8.6 ng/ml (7.2–8.9). Both HCY and CathK were found positively associated with serum phosphorus (r = 0.584, P < 2.01 and r = 0.249, P < 0.05, respectively). Levels of HCY positively correlate with PTH (r = 0.303, P < 0.01) and inversely with Vitamin B12 (r = −0.248, P < 0.05). No significant association was seen between CathK level and 25(OH) D, iPTH, serum calcium.Conclusion:Low bone mass by DXA is a significant problem in postmenopausal females. HCY and CathK do not reliably correlate with bone loss in postmenopausal women although phosphorus metabolism may play a role.

show abstract

Section: Introductionmentioning

confidence: 99%

Relation of bone mineral density with homocysteine and cathepsin K levels in postmenopausal women

Mittal

Verma

Mishra

et al. 2018

Indian J Endocr Metab

View full text Add to dashboard Cite

show abstract

“…Meier et al 28 found that serum Cathepsin K was significantly elevated in postmenopausal women with osteoporosis and decreased after the patients were treated with bisphosphonates. Jahn et al 29 also found that the levels of Cathepsin K were significantly reduced after three to six months treatment with zoledronic acid (P < 0.05), and the level returned to baseline after one year. Recent study has shown that nitrogen-containing bisphosphonates downregulate CTSK in osteoclasts cultured in vitro.…”

Section: Discussionmentioning

confidence: 89%

Association Between CTSK Gene Polymorphisms and Response to Alendronate Treatment in Postmenopausal Chinese Women with Low Bone Mineral Density

Yuan,

Wang,

Liu

et al. 2023

PGPM

View full text Add to dashboard Cite

Purpose The aim of this study was to explore the association between CTSK polymorphisms and the response to alendronate treatment in postmenopausal Chinese women with low bone mineral density. Patients and Methods In this study, 460 postmenopausal women from Shanghai were included. All of them were treated with weekly oral alendronate 70 mg, daily calcium 600 mg and vitamin D 125 IU for a year. Four tag single nucleotide polymorphisms (SNPs) in CTSK gene were genotyped. Bone mineral densities of lumbar spine (L1-L4), femoral neck and total hip were measured at baseline and after 12 months of treatment, respectively. Results After 1-year of treatment, there was no significant differences in BMI between baseline and follow-up. After alendronate treatment, the BMD of L1–4, femoral neck and total hip all increased significantly (all P < 0.001), with average increases of 4.33 ± 6.42%, 1.85 ± 4.20%, and 2.36 ± 3.79%, respectively. There was no significant difference in BMD at L1-L4, the femoral neck and total hip between different genotype groups at baseline ( P >0.05). After 1-year treatment with alendronate, rs12746973 and rs10847 were associated with the % change of BMD at L1-L4 ( P =0.038) and % change of BMD at femoral neck ( P =0.038), respectively. Furthermore, rs10847 was associated with BMD response at femoral neck ( P =0.013). However, the associations were not significant after Bonferroni correction. Conclusion We concluded that the common variations of CTSK gene were potentially associated with the therapeutic response to alendronate treatment in Chinese women with low bone mineral density. However, further validation is needed.

show abstract